source
- Axsome pushes back generic entry for narcolepsy drug until 2040Axsome Therapeutics has successfully delayed generic competition for its narcolepsy drug Sunosi until 2040. The company announced on Wednesday that it has reached a settlement with the last applica…Endpoints · 1mo ago↗ source
- FDA guides pharma on explaining unapproved drugs to payorsBiopharma companies preparing to launch the next practice-changing blockbusters want payors to know what's coming before they ultimately land an FDA approval. The trick is to do that without stretc…Endpoints · 1mo ago↗ source
- Legend surges on early data for ‘in vivo’ lymphoma cell therapyInitial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with “ex vivo” medicines like Novartis’ Kymriah.